scholarly journals Demonstration of Antibiofilm and Antifungal Efficacy of Chitosan against Candidal Biofilms, Using an In Vivo Central Venous Catheter Model

2010 ◽  
Vol 201 (9) ◽  
pp. 1436-1440 ◽  
Author(s):  
Luis R. Martinez ◽  
Mircea Radu Mihu ◽  
Moses Tar ◽  
Radames J. B. Cordero ◽  
George Han ◽  
...  
Keyword(s):  
Central Venous Catheter ◽  
Venous Catheter ◽  
Central Venous ◽  
Antifungal Efficacy

On-line blood viscosity monitoring in vivo with a central venous catheter, using electrical impedance technique

2013 ◽  
Vol 41 ◽  
pp. 595-601 ◽  
Author(s):  
Gheorghe A.M. Pop ◽  
Laurens L.A. Bisschops ◽  
Blagoy Iliev ◽  
Pieter C. Struijk ◽  
Johannes G. van der Hoeven ◽  
...  
Keyword(s):  
Central Venous Catheter ◽  
Blood Viscosity ◽  
Electrical Impedance ◽  
Venous Catheter ◽  
Central Venous ◽  
Impedance Technique ◽  
On Line

scholarly journals In vivo development of heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA), GISA and daptomycin resistance in a patient with meticillin-resistant S. aureus endocarditis

2009 ◽  
Vol 58 (3) ◽  
pp. 376-380 ◽  
Author(s):  
Andrew Kirby ◽  
Kavya Mohandas ◽  
Caroline Broughton ◽  
Timothy J. Neal ◽  
Godfrey W. Smith ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Infective Endocarditis ◽  
Central Venous Catheter ◽  
Venous Catheter ◽  
Resistance Mechanisms ◽  
Central Venous ◽  
Glycopeptide Resistance ◽  
Mrsa Infection ◽  
Central Venous Catheter Infection

We report a patient who developed a meticillin-resistant Staphylococcus aureus (MRSA) central venous catheter infection complicated by infective endocarditis. The patient was initially treated with glycopeptides, which led to the development of heterogeneous glycopeptide resistance, the detection of which required the use of a macro Etest screening test. Subsequently, the causative strain, confirmed by PFGE as a UK epidemic MRSA-15, was treated with daptomycin, and again resistance developed in vivo. The development in vivo of resistance to both these agents suggests that the resistance mechanisms may be associated. We suggest that the clinician managing MRSA infection should anticipate daptomycin resistance when reduced glycopeptide susceptibility is detected.

An effective and biocompatible antibiofilm coating for central venous catheter

2015 ◽  
Vol 61 (5) ◽  
pp. 357-365 ◽  
Author(s):  
Annelisa Farah Silva Paes Leme ◽  
Aline Siqueira Ferreira ◽  
Fernanda Aparecida Oliveira Alves ◽  
Bruna Martinho de Azevedo ◽  
Liza Porcaro de Bretas ◽  
...  
Keyword(s):  
Antimicrobial Activity ◽  
Central Venous Catheter ◽  
Venous Catheter ◽  
Tissue Reaction ◽  
Tissue Response ◽  
Microbiological Analysis ◽  
Central Venous ◽  
Inflammatory Reactions

The aim of this study was to investigate the in vitro and in vivo efficacy and the tissue reaction of an antibiofilm coating composed of xylitol, triclosan, and polyhexamethylene biguanide. The antimicrobial activity was analyzed by a turbidimetric method. Scanning electron microscopy was used to evaluate the antiadherent property of central venous catheter (CVC) fragments impregnated with an antibiofilm coating (I-CVC) in comparison with noncoated CVC (NC-CVC) fragments. Two in vivo assays using subcutaneous implantation of NC-CVC and I-CVC fragments in the dorsal area of rats were performed. The first assay comprised hematological and microbiological analysis. The second assay evaluated tissue response by examining the inflammatory reactions after 7 and 21 days. The formulation displayed antimicrobial activity against all tested strains. A biofilm disaggregation with significant reduction of microorganism’s adherence in I-CVC fragments was observed. In vivo antiadherence results demonstrated a reduction of early biofilm formation of Staphylococcus aureus ATCC 25923, mainly in an external surface of the I-CVC, in comparison with the NC-CVC. All animals displayed negative hemoculture. No significant tissue reaction was observed, indicating that the antibiofilm formulation could be considered biocompatible. The use of I-CVC could decrease the probability of development of localized or systemic infections.

scholarly journals Daptomycin Antibiotic Lock Therapy in a Rat Model of Staphylococcal Central Venous Catheter Biofilm Infections

2011 ◽  
Vol 55 (9) ◽  
pp. 4081-4089 ◽  
Author(s):  
Andrew D. G. Van Praagh ◽  
Tongchuan Li ◽  
Shuxin Zhang ◽  
Anu Arya ◽  
Liping Chen ◽  
...  
Keyword(s):  
Central Venous Catheter ◽  
Venous Catheter ◽  
Central Venous Catheters ◽  
Central Venous ◽  
Effective Treatment Option ◽  
Content Type ◽  
Cyclic Lipopeptide ◽  
Lock Therapy ◽  
Antibiotic Lock

ABSTRACTAntibiotic lock therapy (ALT) is an adjunctive procedure to prevent or treat central venous catheter infections, ensuing catheter-related bacteremia, and catheter-related metastatic infections. Daptomycin is a cyclic lipopeptide that is rapidly bactericidal against methicillin-susceptible and -resistantStaphylococcus aureus. The efficacies of daptomycin against central venous catheter biofilms, catheter-related bacteremia, and catheter-related metastatic infections were evaluated by adapting a previously reported central venous catheter biofilm model in rats. Combined daptomycin ALT and systemic dosing resulted in the clearance of an establishedin vivo S. aureuscentral venous catheter biofilm after just two daily ALT treatments (30 min with daptomycin at 5 mg/ml) with concurrent systemic daptomycin dosing (40 mg/kg of body weight/day subcutaneously [s.c.]; equivalent exposure of 6 mg/kg/day in people). Daptomycin ALT solutions formulated in either saline or lactated Ringer's solution were equally fast in eradicating establishedin vivomethicillin-resistantStaphylococcus epidermidis(MRSE) central venous catheter biofilms. However, the lactated Ringer's formulation was superior to that of saline in sustaining the bacterial clearance of treated central venous catheters (83% versus 50%). In MRSE-infected central venous catheter studies, 3 days of daptomycin or vancomycin ALT (18 h at 5 mg/ml) with systemic s.c. dosing (40 mg/kg/day daptomycin or 100 mg/kg/day vancomycin) was equally effective 1 week posttherapy in maintaining cleared central venous catheters (90% [n= 10] versus 100% [n= 8]). These results suggest that daptomycin ALT, along with systemic dosing, could be an effective treatment option for the prevention or eradication of staphylococcal central venous catheter biofilm infections, thereby reducing the occurrence of catheter-related bacteremia or catheter-related metastatic infections.

scholarly journals In vivo quantification of central venous catheter leak

2005 ◽  
Vol 21 (4) ◽  
pp. 1134-1135 ◽  
Author(s):  
David Philibert ◽  
Simon Desmeules ◽  
Juan Friede ◽  
Mohsen Agharazii
Keyword(s):  
Central Venous Catheter ◽  
Venous Catheter ◽  
Central Venous

scholarly journals Study of in vivo catheter biofilm infections using pediatric central venous catheter implanted in rat

2016 ◽  
Vol 11 (3) ◽  
pp. 525-541 ◽  
Author(s):  
Ashwini Chauhan ◽  
Jean-Marc Ghigo ◽  
Christophe Beloin
Keyword(s):  
Central Venous Catheter ◽  
Venous Catheter ◽  
Central Venous

Inefficiency in 6-Set Requests for Blood Culture Analysis of Cancer Patients with the Central Venous Catheter

2013 ◽  
Vol 3 (3) ◽  
pp. 155
Author(s):  
Dong-Hyun Lee ◽  
Eun-ha Koh ◽  
Sunjoo Kim ◽  
In-Gyu Bae ◽  
Hoon-gu Kim ◽  
...  
Keyword(s):  
Blood Culture ◽  
Central Venous Catheter ◽  
Cancer Patients ◽  
Venous Catheter ◽  
Central Venous
Sign in / Sign up

Export Citation Format

Share Document